PCSK9抑制剂在缺血性脑卒中的潜在应用价值分析

Potential value of PCSK9 inhibitor in ischemic stroke

脑卒中具有高发病率、高致残率、高死亡率、高复发率的特点,其中缺血性脑卒中(IS)是脑卒中最常见的形式。早期针对包括血脂水平在内的IS危险因素进行干预,对于改善IS远期预后具有积极作用。前蛋白转化酶枯草杆菌蛋白酶kexin 9型(PCSK9)是一种可调节低密度脂蛋白受体(LDLR)水平的循环酶,而PCSK9抑制剂可通过阻断PCSK9与LDLR的结合,降低血清低密度脂蛋白胆固醇水平,从而作为一种新型降脂药物在IS防治中展现出极大潜力。本文现围绕PCSK9的生理功能、PCSK9抑制剂的临床应用及PCSK9抑制剂在IS相关病理中的作用等方面的研究进展进行综述,以期为改善IS近期及远期预后提供新思路。

Stroke has characteristics of high incidence,disability,mortality and recurrence rates.Ischemic stroke(IS)is the most prevalent type of stroke.Early management of risk factors associated with IS,such as cholesterol level,has a beneficial impact on improving long-term prognosis.Proprotein converting enzyme subtilin kexin type 9(PCSK9)is a circulating enzyme that regulates low density lipoprotein receptor(LDLR),and PCSK9 inhibitor can reduce serum low density lipoprotein cholesterol by blocking the PCSK9 binding to LDLR;therefore,PCSK9 inhibitor,as a new type of lipid-lowering drug,shows great potential in IS prevention and treatment.This article summarizes the physiological functions of PCSK9,clinical application of PCSK9 inhibitor and role of PCSK9 inhibitor in IS pathologic,aiming to offer novel suggestions for improving short-term and long-term prognoses of individuals with IS.